< %=imgalt%>
US Elections Calendar ~ Barak Obama ~ Iftikhar Muhammad Chaudhry ~ Other International News
Home / International News / Press Releases / 2008 / September / September 19, 2008
Kemin Pharma Opens New Offices in Chennai, India

Top News

Praja Rajyam decides to approach court to vacate the stay on roadshows

Jampui Hills orange production badly affected

Bride-to-be swept to death by sea wave on Proposal Rock

Brangelina donate $100k to Childrens Charity

India, Russia business ties are strong, says Kamal Nath

Security budget for London Olympics set to break record

Retention of peoples DNA records by police banned in Europe

New bone implant technology for tissue engineering on the anvil

Kemin Pharma Opens New Offices in Chennai, India

Herentals, Belgium

Kemin Pharma, a division of Kemin Industries South Asia Private Limited, is pleased to announce the opening of its new offices in Chennai, India. The new facility enables Kemin Pharma to expand its R&D activities in India, as the organization advances its pipeline of human therapeutic products through clinical development and the launch of its lead product, the Bacillus subtilis probiotic PB6 into global markets.

"We have been operating in India over the past year primarily in early clinical research," said Kemin Pharma President Keith A. Bostian. "We are now well poised to increase our team and capabilities in India as an integral component of our global R&D effort. Our plans in India are to move toward earlier preclinical development and discovery stages of the pharmaceutical research process, aiming to become a lead company in the rapidly growing Indian pharmaceutical industry.

The office will initially staff up to 20 clinical research and general management personnel, with research facilities at the same location as well as in Gummidpundi.


The office is located at:
The Trapezium, 1st Floor
#39 Nelson Manickam Road
Aminjikarai, Chennai - 600 029
India
Tel: +91 44 42202800 Fax: +91 44 42202810

Kemin Pharma Bvbc, a member of the Kemin group of companies, with operations in Europe, United States and India, is a biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of infectious and inflammatory diseases. Its mission is to develop new and unique compounds for treatment, including new drugs and treatment approaches against bacteria, viruses and fungi, as well as protozoa, which present a serious, unmet medical challenge throughout the world, and for both acute and chronic gastrointestinal diseases. Its drug development pipeline includes several early clinical-stage candidates as well as an advanced-stage probiotic being launched as a dietary supplement.

The Kemin group of companies strives to improve peoples' lives of half the people in the world every day through its products and services. With over 1,000 employees worldwide, the organization operates in more than 60 countries, with manufacturing facilities in Belgium, Brazil, China, India, Singapore, South Africa, Thailand and the United States.

The Kemin family of companies strives to improve the lives of half the people in the world every day through its products and services. With over 1,000 employees worldwide, the organization operates in more than 60 countries, with manufacturing facilities in Belgium, Brazil, China, India, Singapore, South Africa, Thailand and the United States.

Source: Business Wire (Business Wire India)


AndhraNews.net News for September 19, 2008

Other Press Releases for September 19, 2008